Stockholders' Deficit (Details Textual) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | |||
|---|---|---|---|---|---|---|
May 31, 2019 |
Jun. 30, 2019 |
Jun. 30, 2018 |
Jun. 30, 2019 |
Jun. 30, 2018 |
Dec. 31, 2018 |
|
| Stockholders' Deficit (Textual) | ||||||
| Gain on restructuring of service-related obligations | $ 34,925 | $ 34,925 | ||||
| Series RX-1 Preferred Stock [Member] | ||||||
| Stockholders' Deficit (Textual) | ||||||
| Total preferred stock issued | 1,418,615 | 1,418,615 | 0 | |||
| Preferred stock, shares outstanding | 1,418,615 | 1,418,615 | 0 | |||
| Preferred Stock | $ 1,419 | $ 1,419 | ||||
| Series RX-1 Preferred Stock [Member] | Preferred Stock [Member] | ||||||
| Stockholders' Deficit (Textual) | ||||||
| Aggregate debt | $ 1,826,180 | $ 1,826,180 | ||||
| Total preferred stock issued | 1,418,615 | 1,418,615 | ||||
| Preferred stock, shares outstanding | 1,418,615 | 1,418,615 | ||||
| Preferred Stock | $ 674,103 | $ 674,103 | ||||
| Series RX-1 Preferred Stock [Member] | Preferred Stock Warrant [Member] | ||||||
| Stockholders' Deficit (Textual) | ||||||
| Adjustments to additional paid in capital | 1,789,836 | |||||
| Series RX-2 Preferred Stock Warrant [Member] | ||||||
| Stockholders' Deficit (Textual) | ||||||
| Aggregate debt | $ 490,658 | $ 490,658 | ||||
| Total preferred stock issued | 0 | 0 | 0 | |||
| Total purchase of warrants | 981,316 | 981,316 | ||||
| Price per share | $ 0.50 | $ 0.50 | ||||
| Preferred stock, shares outstanding | 0 | 0 | 0 | |||
| Preferred Stock | ||||||
| Series RX-2 Preferred Stock Warrant [Member] | Preferred Stock Warrant [Member] | ||||||
| Stockholders' Deficit (Textual) | ||||||
| Aggregate debt | $ 490,658 | $ 490,658 | ||||
| Total purchase of warrants | 981,316 | 981,316 | ||||
| Price per share | $ 0.50 | $ 0.50 | ||||
| Description of preferred stock warrants | (i) the effectiveness of any capital reorganization of the Company, any reclassification of the capital stock of the Company, any consolidation or merger of the Company with or into another corporation (other than a consolidation or merger in which the Company is the surviving entity), or any transfer of all or substantially all of the assets of the Company, or other similar occurrence involving the Company, or (ii) December 31, 2021. If all Series RX-2 warrants are exercised to purchase a total of 981,316 shares of Series RX-2 Preferred Stock at $0.50 per share, the amount of cash realizable by the Company is $490,658. | |||||
| Preferred stock, shares outstanding | 981,316 | 981,316 | ||||
| Preferred Stock | $ 308,133 | $ 308,133 | ||||
| Gain on restructuring of service-related obligations | 182,523 | |||||
| Series RX-3 Preferred Stock Warrant [Member] | ||||||
| Stockholders' Deficit (Textual) | ||||||
| Aggregate debt | $ 1,397,647 | $ 1,397,647 | ||||
| Total preferred stock issued | 0 | 0 | 0 | |||
| Total purchase of warrants | 481,212 | 481,212 | ||||
| Price per share | $ 5.00 | $ 5.00 | ||||
| Preferred stock, shares outstanding | 0 | 0 | 0 | |||
| Preferred Stock | ||||||
| Series RX-3 Preferred Stock Warrant [Member] | Preferred Stock Warrant One [Member] | ||||||
| Stockholders' Deficit (Textual) | ||||||
| Aggregate debt | $ 1,397,647 | $ 1,397,647 | ||||
| Total purchase of warrants | 481,212 | 481,212 | ||||
| Price per share | $ 5.00 | $ 5.00 | ||||
| Description of preferred stock warrants | ▪ until such time following the date of any Series RX-3 Warrant, if at all, that the gross profit of the Company as reported in the Company's consolidated and audited financial statements contained within its Annual Report on Form 10-K (the "Form 10-K") filed with the U.S. Securities and Exchange Commission (the "SEC") for any then preceding fiscal year during which such Series RX-3 Warrant is outstanding ("Reported Annual Gross Profit"), equals or exceeds $1,000,000, such Series RX-3 Warrants shall not be exercisable for any shares of Series RX-3 Preferred Stock; ▪ upon achievement for the first time following the date of any Series RX-3 Warrant, if at all, of a Reported Annual Gross Profit equal to or exceeding $1,000,000, then such Series RX-3 Warrant shall become exercisable for twenty-five percent (25%) of the number of shares of Series RX-3 Preferred Stock for which it is stated to be exercisable in the aggregate as of the date of the filing of the Form 10-K in which the corresponding financial statements have been included; ▪ upon achievement for the first time following the date of any Series RX-3 Warrant, if at all, of a Reported Annual Gross Profit equal to or exceeding $2,000,000, then such Series RX-3 Warrant shall become exercisable for twenty-five percent (25%) of the number of shares of Series RX-3 Preferred Stock for which it is stated to be exercisable in the aggregate as of the date of the filing of the Form 10-K in which the corresponding financial statements have been included; provided, however, that, if the achievement of the Reported Annual Gross Profit hurdle set forth in subsection (ii) above shall occur concurrently with the achievement of the Reported Annual Gross Profit hurdle set forth in this subsection (iii), then and in such event, the vesting of the exercise rights relative to shares of Series RX-3 Preferred Stock under such Series RX-3 warrant shall be cumulative (i.e. fifty percent [50%]); ▪ upon achievement for the first time following the date of any Series RX-3 Warrant, if at all, of a Reported Annual Gross Profit equal to or exceeding $4,000,000, then such Series RX-3 Warrant shall become exercisable for twenty-five percent (25%) of the number of shares of Series RX-3 Preferred Stock for which it is stated to be exercisable in the aggregate as of the date of the filing of the Form 10-K in which the corresponding financial statements have been included; provided, however, that, if the achievement of the Reported Annual Gross Profit hurdle set forth in subsection (ii) and/or (iii) above shall occur concurrently with the achievement of the Reported Annual Gross Profit hurdle set forth in subsection (iv), then and in such event, the vesting of the exercise rights relative to shares of Series RX-3 Preferred Stock under such Series RX-3 Warrant shall be cumulative (i.e. either fifty percent [50%] or seventy-five percent [75%], as applicable); ▪ upon achievement for the first time following the date of any Series RX-3 Warrant, if at all, of a Reported Annual Gross Profit equal to or exceeding $8,000,000, then such Series RX-3 Warrant shall become exercisable for twenty-five percent (25%) of the number of shares of Series RX-3 Preferred Stock for which it is stated to be exercisable in the aggregate as of the date of the filing of the Form 10-K in which the corresponding financial statements have been included; provided, however, that, if the achievement of the Reported Annual Gross Profit hurdle set forth in subsection (ii), (iii), and/or (iv) above shall occur concurrently with the achievement of the Reported Annual Gross Profit hurdle set forth in this subsection (v), then and in such event, the vesting of the exercise rights relative to shares of Series RX-3 Preferred Stock under such Series RX-3 Warrant shall be cumulative (i.e. either fifty percent [50%], seventy-five percent [75%], or one hundred percent [100%], as applicable). | |||||
| Preferred stock, shares outstanding | 481,212 | 481,212 | ||||
| Preferred Stock | $ 1,737,175 | $ 1,737,175 | ||||
| Gain on restructuring of service-related obligations | $ 1,397,644 | |||||
| Notes Payable [Member] | ||||||
| Stockholders' Deficit (Textual) | ||||||
| Accrued interest | $ 55,237 | |||||
| Common stock | 7,890,958 | |||||